To further complicate clinicians’ treatment decisions, Padcev-Keytruda has become the new standard of care in first-line metastatic bladder cancer, raising the possibility that some physicians might ...

Circulating tumor DNA, or ctDNA, can predict metastatic risk in patients who receive bladder-sparing treatment for muscle-invasive bladder cancer, but it is not a good predictor of local recurrence ...

What Is Zusduri Used For? Zusduri is used to treat a certain type of recurrent, persistent bladder cancer known as LG-IR-NMIBC. About 75% of people with bladder cancer present with non-muscle invasive ...

A trial tested an enhanced recovery after surgery (ERAS) protocol in patients who underwent ambulatory transurethral resection (TURBT) of bladder cancer.

UConn Center on Aging researchers have published a new editorial in the journal Aging titled "Polyploidy-induced senescence: Linking development, differentiation, repair, and (possibly) cancer?" In ...

Bladder cancer frequently announces itself through symptoms that patients dismiss as minor urinary issues, and that delay ...

Although bladder cancer ranks as the sixth most common cancer in the United States, with approximately 85,000 new cases diagnosed each year, it continues to receive limited awareness, advocacy, and ...

Bladder cancer signs and symptoms can vary from person to person. The most common symptom is blood in the urine, also called hematuria. While this can turn the urine into a red or rusty color, it may ...

Bladder cancer is the fourth most commonly diagnosed cancer in men in the United States and the 10th leading cause of cancer deaths. Many treatments can be used for bladder cancer, and the kind of ...

Bladder cancer affects approximately 83,000 Americans each year, yet remains one of the most overlooked forms of cancer despite having excellent survival rates when caught early. This disconnect ...